Blog - Page 3143 of 5752

WednesdayFeb 20, 2013 3:10 pm

NovaBay Pharmaceuticals, Inc. (NBY) Receives International Nonproprietary Name (INN) from World Health Organization

NovaBay Pharmaceuticals, Inc. (NBY) Receives International Nonproprietary Name (INN) from World Health Organization Today, biotechnology company NovaBay Pharmaceuticals announced it has received approval from the World Health Organization for the international nonproprietary name (INN) “auriclosene” for NVC-422, its lead Aganocide compound. Facilitating the identification of active pharmaceutical ingredients, INNs have unique, globally recognized names. Aganocides, NovaBay’s first-in-class topical antimicrobial compounds, are active against viruses, fungi, and bacteria – including the bacteria that grow and thrive under biofilm. In-vitro and in-vivo tests have shown that these non-systemic, non-antibiotic compounds don’t give rise to bacterial or fungal resistance. Currently, Phase 2 studies…

WednesdayFeb 20, 2013 3:09 pm

Bergamo Acquisition Corp. (BGMO) Business Model

Bergamo Acquisition is a global and diversified holding company seeking strategic investments in a variety of industries, including alternative energy, biotechnology and healthcare, commercial and investment banking, and hedge funds. Bergamo plans to effect equity investments, management buy-outs, friendly mergers, and value-accretive capital projects. At times the company may provide debt financing as a primary investor in the form of bi-laterally negotiated private placements. Using a unique but solid funding process, Bergamo has raised substantial funds to pursue its investment targets. The company has fiduciary discretion over these funds and will direct their disposition in line with its overall strategy.…

WednesdayFeb 20, 2013 3:08 pm

Soligenix, Inc. (SNGX) Submits Contract Proposal for Multi-Million Dollar Contract with BARDA

Soligenix, a development stage biopharmaceutical company focused on treatments for gastrointestinal diseases, has submitted a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures. This submission is in regards to a potential multi-year, multi-million dollar contract to develop OrbeShield as a medical countermeasure (MCM) to treat gastrointestinal acute radiation syndrome (GI ARS), a condition that can occur after toxic radiation exposure. BARDA invited Soligenix to submit its proposal in response to a Broad Agency Announcement for advanced research and development and eventual licensure/approval of effective MCMs to…

WednesdayFeb 20, 2013 10:45 am

Cardium Therapeutics, Inc. (CXM) and the Generx Strategy

Cardium Therapeutics’ lead clinical development product candidate is Generx, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Unlike other coronary drug therapeutics, Generx is designed to actually stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe. Generx is…

WednesdayFeb 20, 2013 7:51 am

Vitesse Semiconductor Corp. (VTSS) VeriTime™ Announced as Finalist for 2013 China ACE Awards

Vitesse Semiconductor, a leading provider of advanced IC solutions for Carrier and Enterprise networks, announced that its VeriTime™ chipset was chosen as a finalist for the 2013 China Annual Creativity in Electronics (ACE) Awards in the Product of the Year, Mixed Signal Controller/Processor/SoC category. The nominated chipset is comprised of SynchroPHY™ 1 Gigabit Ethernet (GE), 10GE and 10GE OTN PHYs, and Carrier Ethernet Switch Engines, which makes use Vitesse’s IEEE1588v2 LTE-Advanced-ready VeriTime technology. Organized by Global Sources, the China ACE Awards honor the technologies, companies, and people that shape innovative electronics design in mainland China. Qualified by the ACE Award…

WednesdayFeb 20, 2013 7:50 am

VIASPACE, Inc. (VSPC) Signs Contract with $300 Million Company, Reports Energy Crop Growth in Nicaragua

Today before the opening bell, VIASPACE announced that it has entered into a contract with AGRICORP of Managua, Nicaragua, and is growing Giant King™ Grass on land owned by them. It is anticipated that AGRICORP shareholders and VIASPACE will co-develop a biomass electric power plant fueled by Giant King Grass in Nicaragua. A subsidiary of Grain Hill, AGRICORP has sales of $300 million per year with operations in Nicaragua, Costa Rica, and El Salvador. Grain Hill is a diversified agro-industrial business group and well known as the largest rice company in Nicaragua with 65% market share. AGRICORP/Grain Hill is engaged…

WednesdayFeb 20, 2013 7:50 am

ISC8, Inc. (ISCI) Launches Malware Research Team to Combat Malware Threats, Advance Cybersecurity Solutions

ISC8, a developer of intelligent cybersecurity, has established ISC8’s Malware Research Team (MRT) comprised of network security researchers, advisors, analysts, and engineers, each backed with inventive malware expertise that will be incorporated into the company’s Cyber adapt™ solution. Cyber adAPT function is to identify advanced threats in enterprise, service provider, and defense networks. In an age of rapidly advancing computer technology, advanced malware grows at an increasingly commensurate pace. ISC8’s MRT was implemented to work in collaboration with this solution to identify emerging threats. ISC8 says that while the MRT first and foremost was established to protect customers, the team…

WednesdayFeb 20, 2013 7:49 am

Viscount Systems, Inc. (VSYS) Acquires Contract to Secure Facility for International Manufacturer

Viscount Systems, a leading-edge supplier of security systems and software, this morning announced that it has received an initial order for its Freedom access control solution from an international manufacturer and supplier of industrial solutions. According to the press release, this contract could potentially lead to securing a total of 65 facilities owned or managed by this client. The systems to be installed will include Freedom access control running on Viscount’s patent-pending Microsoft Active Directory platform. Microsoft’s virtualization platform that makes it easier for businesses to virtualize existing server hardware assets and move them to the cloud. “This project demonstrates…

TuesdayFeb 19, 2013 2:27 pm

Viscount Systems, Inc. (VSYS) Thinks It’s Time for a Change

Viscount Systems designs, manufactures, and services a range of access control and security products for clients around the world. The company focuses on door access control, emergency communications, and other security systems and components currently installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices. They’ve been in the industry since 1969, but today they’re one of the few that have positioned themselves for major security changes that are long overdue. Access control, a $10 billion part of the $100 billion security market, has been dominated by multi-national corporations, such as Honeywell and UTC.…

TuesdayFeb 19, 2013 10:39 am

Savient Pharmaceuticals, Inc. (SVNT) and Sobi Announce Agreement to Co-Promote Kineret in the US

Savient Pharmaceuticals is a specialty biopharmaceutical company whose mission is to develop and commercialize pharmaceutical specialty products. The company announced today that it and Swedish Orphan Biovitrum AB (SOBI) have entered into an agreement for the co-promotion of Kineret (anakinra) in the United States. Sobi, an international specialty healthcare company dedicated to treatments for rare diseases, has a product portfolio primarily focused on inflammation and genetic diseases, with three late-stage biological development projects. Additionally, the company markets a portfolio of specialty and rare products with overseas partners such as Savient. Kineret, a recombinant IL-1 receptor antagonist, is a treatment for…

Site Search

Company Search